The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Dialectic Therapeutics
Leadership - Dialectic Therapeutics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Bristol-Myers Squibb; Dialectic Therapeutics; Intuitive Surgical; Johnson & Johnson; Merck; Regeneron
Consulting or Advisory Role - Binhui Biopharmaceuticals, Ltd.; Synlogic
Research Funding - Agenus; Alkermes; Arvinas; AstraZeneca; BerGenBio; Daiichi Sankyo; Epizyme; Gan & Lee; Genmab; GlaxoSmithKline; Harpoon Therapeutics; Hutchison MediPharma; Jounce Therapeutics; Laekna Therapeutics; Mirati Therapeutics; Mundipharma; Novartis Pharmaceuticals UK Ltd.; Odonate Therapeutics; Onconova Therapeutics; ORIC Pharmaceuticals; Pfizer; Rgenix; Shasqi Inc.; Surface Oncology; Synlogic; Takeda; Xencor
 
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Certis Oncology Solutions; Genentech; Illumina; Lilly; Merck; Rakuten Medical; Tempus
Research Funding - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Fate Therapeutics; Genocea Biosciences; Iovance Biotherapeutics; Lilly; Merck; Pfizer; Roche/Genentech
A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors.
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Advanced Accelerator Applications; Alkermes; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Helsinn Therapeutics; Merck Serono; Pfizer
Speakers' Bureau - Bayer; Exelixis; Pfizer
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Merck KGaA
 
Sonam Puri
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst)
 
Lanjia Lin
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Mark Chao
Employment - Gilead Sciences
Stock and Other Ownership Interests - Bioverge; Chimera Bioengineering; Hepatx; IconOVir Bio
Consulting or Advisory Role - Bioverge; Chimera Bioengineering; Foresite Capital; Hepatx; IconOVir Bio; Leukemia and Lymphoma Society; TigaTx
Patents, Royalties, Other Intellectual Property - Stanford University
 
Giri Ramsingh
Employment - Gilead Sciences
Stock and Other Ownership Interests - Exelixis; Gilead Sciences; Roche
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); EcoR1 Capital; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; Mundipharma; Seagen; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Day One Therapeutics (Inst); Dynavax Technologies (Inst); Elevation Oncology (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Bayer
 
James F. Strauss
No Relationships to Disclose
 
Sandip P. Patel
No Relationships to Disclose